William Forbes serves as the Chief Development Officer at Heron Therapeutics Inc., a biopharmaceutical company focused on improving the lives of patients by developing innovative treatments for unmet medical needs. In his role, Forbes is responsible for overseeing the company's product development strategy, which includes managing clinical trials, regulatory affairs, and the overall advancement of Heron's pipeline. His leadership has been instrumental in guiding the company through the complex landscape of drug development, ensuring that Heron continues to bring new and effective therapies to market. Before joining Heron Therapeutics, Forbes had an extensive career in the pharmaceutical industry, with over 20 years of experience in drug development and regulatory affairs. He held senior positions at several leading pharmaceutical companies, where he successfully led the development and approval of multiple drugs across various therapeutic areas. Forbes is well-regarded for his expertise in navigating the regulatory environment and his ability to build strong relationships with regulatory agencies worldwide. His strategic vision and deep understanding of the drug development process have been key factors in his success and have greatly benefited Heron Therapeutics since his appointment. Under Forbes' leadership, Heron Therapeutics has made significant strides in its mission to develop innovative treatments. One of his notable achievements at the company includes the successful development and FDA approval of Zynrelef, a non-opioid pain management solution that has provided a new option for patients recovering from surgery. Forbes' commitment to advancing Heron's pipeline and his dedication to improving patient outcomes have solidified his reputation as a valuable asset to the company and the broader pharmaceutical industry.